Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fundação de Amparo à Pesquisa do Estado de São Paulo | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators propose a randomized clinical trial comparing the effect of 30 mcg ethinyl estradiol and LNG 150 combination oral contraceptive pills versus placebo, or LNG-IUS or Etonogestrel-releasing contraceptive implant (Implanon)on breast-milk intake and infant growth in exclusively breastfeeding mother-infant pairs. Mother-infant pairs will be randomly assigned either 30 microgram ethinyl estradiol combination oral contraceptive pills or identical placebo to start on post-partum day number 42 or Implanon implants or a LNG-IUS. All women will be offered nonhormonal contraceptives prior to randomization. The pairs will then be followed for four weeks. During this follow-up period, breast-milk intake will be quantified by administering deuterium oxide to exclusively breast-feeding mothers and measuring the enrichment of deuterium oxide in the saliva of their infants, otherwise known as the dose-to-mother method of Coward.17 Additionally, maternal and infant anthropometric measurements will be collected -- both as a value necessary to implement the breast-milk quantification method, as well as an outcome for analysis, and a daily diary will be kept by the women participating in the study that records infant feeds and diaper changes.
Women where allocated to an oral combined contraceptive pill, or placebo or a LNG-IUS or a etonogestrel-releasing subdermal contraceptive implant at day 42 after delivery. After the provision of the contraceptive method a 0.5 mg/kg of deuterium 99.99% according to the weight of the mother will be administer to all women. One sample of saliva from the mother and the child will be collected every day until 21 days after enrollment. Additionally, weight, height and size of the leg of each child will be measured at baseline, at the day 11 and at the day 21 after enrollment. Also, a diary with information of change of diapers and number of breastfeeding will be kept by each mother.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Combined oral contraceptive | Active Comparator | 10 women will receive COC during breastfeeding |
|
| Levonorgestrel intrauterine system | Active Comparator | 10 women will receive a LNG-IUS during breastfeeding |
|
| Implanon | Active Comparator | 10 women will receive Implanon during breastfeeding |
|
| TCu380A intrauterine device | Active Comparator | 10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LNG-IUS | Device | 10 women will receive the LNG-IUS during breastfeeding |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of infant weight, height and size of the tibial | The study have the purpose to evaluate the infant weight, height and size of the tibial in infant who breastfeeding on demand exclusively and their mother were either users of a combined oral contraceptive, placebo, etonogestrel-releasing subdermal contraceptive implant or levonorgestrel-releasing intrauterine system. Additionally, pregnancy effectiveness and any adversse event will record in all groups of women. | women and children will be evaluated at time frame from day 42 through day 64 post-partum |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Luis Bahamondes, MD | University of Campinas | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Campinas | Campinas | São Paulo | 13083-888 | Brazil |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23623474 | Derived | Bahamondes L, Bahamondes MV, Modesto W, Tilley IB, Magalhaes A, Pinto e Silva JL, Amaral E, Mishell DR Jr. Effect of hormonal contraceptives during breastfeeding on infant's milk ingestion and growth. Fertil Steril. 2013 Aug;100(2):445-50. doi: 10.1016/j.fertnstert.2013.03.039. Epub 2013 Apr 23. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013851 | Thinness |
| D001942 | Breast Feeding |
| ID | Term |
|---|---|
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D005247 | Feeding Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Implanon | Device | 60 mcg/day contraceptive implant |
|
|
| 30 mcg EE and 150 LNG oral contraceptive (Microvlar) | Drug | 10 women will receive oral contraceptive during breastfeeding |
|
|
| TCu380A copper-intrauterine device | Device | Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group |
|
|
| TCu380A intrauterine device | Device | 10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding |
|
|
| D001519 | Behavior |